| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Improved survival with ipilimumab in patients with metastatic melanoma.
|
N Engl J Med
|
2010
|
67.34
|
|
2
|
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
|
N Engl J Med
|
2011
|
45.46
|
|
3
|
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
|
Lancet Oncol
|
2009
|
8.68
|
|
4
|
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
|
Lancet
|
2012
|
6.21
|
|
5
|
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
|
Clin Cancer Res
|
2009
|
5.99
|
|
6
|
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
|
J Clin Oncol
|
2011
|
2.87
|
|
7
|
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
|
J Clin Oncol
|
2002
|
2.26
|
|
8
|
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
|
J Clin Oncol
|
2013
|
2.11
|
|
9
|
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.
|
Invest New Drugs
|
2010
|
2.09
|
|
10
|
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.
|
Cancer Immun
|
2010
|
2.07
|
|
11
|
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
|
Ann N Y Acad Sci
|
2013
|
2.03
|
|
12
|
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.
|
Clin Cancer Res
|
2006
|
1.72
|
|
13
|
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
|
J Clin Oncol
|
2005
|
1.40
|
|
14
|
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
|
J Clin Oncol
|
2002
|
1.38
|
|
15
|
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
|
J Clin Oncol
|
2005
|
1.37
|
|
16
|
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.
|
Melanoma Res
|
2011
|
1.35
|
|
17
|
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
|
Clin Cancer Res
|
2007
|
1.33
|
|
18
|
Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
|
Cancer Res
|
2006
|
1.32
|
|
19
|
Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
|
J Invest Dermatol
|
2006
|
1.26
|
|
20
|
Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients.
|
Clin Chem
|
2005
|
1.25
|
|
21
|
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
|
Cancer
|
2010
|
1.24
|
|
22
|
Sunitinib therapy for melanoma patients with KIT mutations.
|
Clin Cancer Res
|
2012
|
1.23
|
|
23
|
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
|
Clin Cancer Res
|
2010
|
1.19
|
|
24
|
Quantification of circulating DNA in the plasma and serum of cancer patients.
|
Ann N Y Acad Sci
|
2004
|
1.18
|
|
25
|
Estrogen receptor-alpha methylation predicts melanoma progression.
|
Cancer Res
|
2006
|
1.18
|
|
26
|
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2013
|
1.15
|
|
27
|
Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
|
Ann Surg
|
2002
|
1.11
|
|
28
|
An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.
|
J Neurooncol
|
2002
|
1.10
|
|
29
|
mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads.
|
Clin Chem
|
2009
|
1.07
|
|
30
|
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
|
J Clin Oncol
|
2006
|
1.03
|
|
31
|
Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.
|
J Natl Cancer Inst
|
2004
|
0.97
|
|
32
|
Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
|
Clin Cancer Res
|
2005
|
0.96
|
|
33
|
Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine.
|
J Clin Oncol
|
2002
|
0.94
|
|
34
|
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.
|
BMC Cancer
|
2009
|
0.93
|
|
35
|
Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome.
|
Cancer Res
|
2004
|
0.90
|
|
36
|
Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach.
|
Cancer Treat Rev
|
2010
|
0.87
|
|
37
|
Biochemotherapy for metastatic melanoma with limited central nervous system involvement.
|
Oncology
|
2003
|
0.81
|
|
38
|
Systemic treatment of metastatic melanoma: new approaches.
|
J Surg Oncol
|
2011
|
0.77
|
|
39
|
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.
|
J Immunother
|
2017
|
0.75
|